LARAZOTIDE

Description

Larazotide acetate (formerly AT-001, Alba Therapeutics) is an oral peptide derived from the zonula occludens toxin secreted by Vibrio Cholera. As a tight junction regulator, it binds to receptors of apical intestinal cells and prevents opening of epithelial intestinal tight junctions induced by bacterial antigens, pro-inflammatory cytokines, or gliadin peptides. Its mechanism has been supported by in vitro and in vivo studies, making it a suitable candidate to treat celiac disease. Larazotide acetate aids in the restoration of the intestinal barrier function by intervening in the zonulin-mediated signaling pathway, blocking zonulin receptors, preventing tight junction disassembly, and minimizing the increase in intestinal permeability. Moreover, larazotide acetate is involved in rearranging several tight junction proteins to promote tight junction assembly. Larazotide acetate also plays a role in stimulating tight junction closure. BOTTLE DESIGN MAY VARY LARAZOTIDE COA